PDCD1 and uveal melanoma: In the absence of randomized phase III evidence for OS benefit from anti-PD1/L1 ICI regimens in patients with mUM, there is a clinical need to define high-risk prognostic features in this patient population and to ultimately identify predictive biomarkers of ICI response that could assist in the optimal treatment selection for uveal melanoma patients.